Search Tufts Medicine

Study DSP-5336-101 is a Phase 1/2, open-label, dose-escalation, dose-expansion study in which the safety, PK, pharmacodynamics, and clinical activity of orally administered DSP-5336 will be evaluated in adult patients with relapsed or refractory AML, ALL, or acute leukemia of ambiguous lineage, as well as in adult patients with high-risk relapsed or refractory MDS or relapsed/refractory MM.

12-Week open label clinical trial looking at the effects of nicotinamide riboside on bioenergetic metabolism, oxidative stress, and cognition in Mild Cognitive Impairment and Mild Alzheimer's Disease.

Observational study to evaluate new imaging methods and software of the Topcon prototype OCT instrument for ocular blood flow imaging of patients with different retinal diseases and healthy volunteers.

This is a single center prospective cohort study. The cohort (interventional) patients will receive the study intervention (ABCLO). The control group retrospective patients that were previously managed at the same center, regardless of the technique or the device used to close the OA.

Breast cancer (BC) is the leading cause of cancer and the second most common cause of cancer related mortality in the United States. Although the prognosis of patients with BC has greatly improved over the past few years, there are still many unanswered questions. There is growing interest in identifying markers for treatment de-escalation or intensification in early and advanced breast cancer as well as in ductal carcinoma in situ (DCIS). Additionally, there are well known differences in disease biology and outcomes in groups from diverse genetic ancestry.

This is a prospective, multi-center, multi-arm, double-blind, randomized, controlled platform trial evaluating antiviral and other therapeutics for use in the treatment of Post-Acute Sequelae of COVID-19 (PASC). The hypothesis is that persistent viral infection and/or overactive/chronic immune response are underlying contributors to PASC and that antiviral and other applicable therapies may result in viral clearance or decreased inflammation and improvement in PASC symptoms.

This is a Phase 2/3 study designed to evaluate the efficacy and safety of BIIB059 for the treatment of participants with active SCLE and/or CCLE with or without systemic manifestations and refractory and/or intolerant to antimalarial therapy.

The primary goal of this study is to improve our understanding of changes in skeletal muscle mass in the arms and the legs during a hospitalization for advanced HF. We plan to measure muscle thickness with an ultrasound machine in two locations on the body (the outer thigh and the upper arm muscle, of the dominant side) from the time a patient is first admitted to the ICU with HF as well as before and after any surgical HF therapies.

This study will collect real-world clinical and patient reported outcomes (PRO) and diary data from eligible patients with documented Human Epidermal Growth Factor Receptor 2 (HER2+) [globally] or HER2-low [North America only] in routine clinical practice.

Patients receiving commercial CAR-T therapy for their clinical care are invited to provide 5 blood draws at the time blood is drawn for their clinical care. The samples will be used to help develop a new technology for detecting CAR-T cells in the blood.

This study seeks to obtain cancer and healthy tissue from women with metastatic ovarian cancer. The tissue will be used in a preclinical study to develop a multi-scale imaging probe that can better detect cancer metastases.

This research study will investigate the independent effects of an environmental intervention (E only), an individual-level eHealth phone program intervention (I only), or both (E+I) on changes in moderate intensity physical activity. A cluster randomized design will be implemented whereby all residents of one of 12 of Boston's public housing developments (PHDs) will be randomized to one of the four study groups (E only, I only, E+I, or control). The findings will inform future health promotion efforts among residents in public housing developments

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma, who have achieved a partial response or complete response after completing at least 12 weeks of platinum-based therapy.

This study will evaluate the safety and effectiveness outcomes of FRED X device in a population of patients that aligns with the indications for use of the FRED device. The data generated from this study will be compared to the safety and effectiveness of the FRED device by meeting the same performance goals established for the FRED pivotal study.

We are interested in the side effects of medications commonly used to treat diseases like chronic myelogenous leukemia. In particular, we are interested in the effects on blood vessel cells, white blood cells, and platelets. Our data will allow us to determine any effects that these medications have on human white blood cells and platelets.

This is a Phase 2b study to evaluate the safety, tolerability and preliminary efficacy of autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with GMG. The cell product will be referred to as "Descartes-08".

Patients with Chronic Kidney Disease(CKD) who receive medical care at Tufts Medicine will be invited to join a CKD research registry. The registry will record their medical information related to CKD and future researchers will be allowed to contact patients to ask if they would like to join a CKD related research study. There is nothing patients have to do once they join the registry, and joining a CKD research study is entirely optional.

Gore has developed and manufactures the GORE® SYNECOR Intraperitoneal Biomaterial device (GORE® SYNECOR IP Device) to offer clinicians a mesh material intended for the repair of ventral/incisional hernias that may require the addition of a nonabsorbable reinforcing or bridging material. The primary study objective is to assess SYNECOR Biomaterial performance on incisional hernia patients over an extended amount of time through multiple methods. The secondary study objective is to conduct configuration-specific assessments to address areas of medical interest.

In this study, researchers are hoping to improve post-operative pain control and reduce opioid use using a technique called TAP block. A TAP block is a form of pain relief that "blocks" the pain receptors in a person's abdomen and can be performed during minimally invasive hysterectomy. Enrolled participants undergoing minimally invasive hysterectomy will be randomized to three pain control or TAP block options.

Percutaneous Coronary Intervention (PCI) involves positioning of a stent under Xray guidance to treat coronary arterial stenosis. It then requires intraprocedural assessment of stent positioning and deployment. Standard assessment is done using 2-dimensional angiography possibly augmented with stent enhancement algorithms (e.g. StentViz, GE HealthCare) and/or Intravascular Imaging such IVUS. IVUS brings excellent visualization and clinical information, but it is limited by catheter cost, workflow and time.